ChemicalBook > Product Catalog >API >Hormones and the Endocrine System >Pancreatic hormone and blood sugar regulation >Nateglinide


Nateglinide Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Products Intro: Product Name:Nateglinide
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Nateglinide
Purity:99% Package:100g,500g,1kg,5kg,10kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: Product Name:Nateglinide
Purity:0.99 Package:25KG,5KG;1KG;500G
Company Name: PI & PI BIOTECH INC.
Tel: 18371201331
Products Intro: Product Name:Nateglinide
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Remarks:N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine
Company Name: Nanjing ChemLin Chemical Industry Co., Ltd.
Tel: 025-83697070;
Products Intro: CAS:105816-04-4
Purity:98% Package:g-Kg Remarks:White crystal powder

Lastest Price from Nateglinide manufacturers

  • Nateglinide
  • US $2.00 / kg
  • 2019-07-06
  • CAS:105816-04-4
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
Nateglinide Basic information
Physical and Chemical Properties Hypoglycemic agents Uses
Product Name:Nateglinide
Synonyms:(-)-n-(trans-4-isopropylcyclohexanecarbonyl)-d-phenylalanine;ay4166;Nateglinide(H);trans-d-phenylalanin;N-(Trans-4-Isopropylcyclohexyl-1-Carbonyl)-D-Phenylalamine;trans-d-phenylalanine;NATAGLINIDE;Nateglinide (200 mg)
Product Categories:Aromatics;Antidiabetic;STARLIX;APIs;Health & Beauty;Amino Acids & Derivatives;Intermediates & Fine Chemicals;Pharmaceuticals;Active Pharmaceutical Ingredients;API
Mol File:105816-04-4.mol
Nateglinide Structure
Nateglinide Chemical Properties
Melting point 137-141°C
alpha D20 -9.4° (c = 1 in methanol)
Boiling point 527.6±39.0 °C(Predicted)
density 1.104±0.06 g/cm3(Predicted)
storage temp. Room temp
solubility DMSO: >5mg/mL
form solid
color white to off-white
Merck 14,6428
CAS DataBase Reference105816-04-4(CAS DataBase Reference)
Safety Information
Hazard Codes Xn
Risk Statements 22
Safety Statements 24/25-36
WGK Germany 3
RTECS SQ7318950
HS Code 29242990
ToxicityLD50 orally in rats: >2.0 g/kg (Hasegawa)
MSDS Information
Nateglinide English
Nateglinide Usage And Synthesis
Physical and Chemical PropertiesWhite or almost white crystalline powder, odorless, bitter taste. It is soluble in methanol, ethanol, chloroform, dissolved in acetone, ethyl ether, almost insoluble in water. Valid form used in clinic is H-type, mp 137~141 ℃. [Α] D-37.5 °, the maximum UV absorption wavelength in methanol is 252,257,263nm.
The above information is edited by the chemicalbook of Tian Ye.
Hypoglycemic agentsNateglinide and mitiglinide, repaglinide are three commonly used non-sulfonylurea oral hypoglycemic agents for insulin secretion,it is successfully developed for the first time by the Japanese company Ajomoto , its chemical structure belongs to carbamoylmethyl-benzoic acid (CMBA), it belongs to D-phenylalanine derivatives, it is a new generation of antidiabetic drugs having amino acid structure ,it is an amino acid derivative prompting insulin secretion, it is also currently the only non-sulfonylureas insulinotropic agent having amino acid structure. The mechanism is mainly through binding the pancreatic β cell sulfonylurea receptor, blocking islet cell ATP-sensitive potassium channels, leading to membrane depolarization, causing the calcium channe lopen to promote insulin secretion. This product is a new type of meal blood glucose regulator, which can effectively control the postprandial blood glucose levels, with rapid onset, short duration of action, low incidence of cardiovascular side effects and hypoglycemia and other characteristics.
Oral bioavailability is 72%, after 15min it can produce insulin secretion effect, Tmax is 0.5~0.9 h, 0.2 h insulin levels achieve peak ,after 1.5 h it is similar to placebo. The plasma protein binding rate is 99%. After reaching plasmapeak , plasma concentrations decline rapidly.T1/2 of oral administration of 120 mg and intravenous injection 60 mg of is 1.5 to 1.7 hours, and the plasma clearance is 7.4 hours. It is metabolized in the liver by isoenzyme CYP2C9 and CYP3A4 way. The main metabolites are products after isomeric oxidation,it can be hydroxyl, diastereomers, isopropyl isomer or unsaturated aliphatic isomers.The main metabolites in plasma and urine are metabolites after the hydroxylation of isopropyl methine family (me-thine carbon) . About 2/3 nateglinide is excreted from the fecal , and the rest is excreted in the urine. Such excretion way is beneficial to elderly Ⅱ diabetes mellitus with renal dysfunction. nateglinide eliminate T1/2 is 1.4 h, because nateglinide T1/2 is short, there is no report yet about the drug accumulation in the body . Long-term use of nateglinide does not produce drug-induced hypoglycemia caused by drug accumulation .It is used for the treatment of diet therapy, exercise therapy and mild to moderate non-insulin dependent (Ⅱ type) diabetes which taking α-glucosidase inhibitor can not control. The results show that: nateglinide can be used more physiologically for meal glucose control, there is less opportunity for contact with insulin and hypoglycemia which allows patients to flexibly plan scheduling mealtimes, which means there is medication while eating, not eating no medication.
UsesIt is used for the treatment of diabetes
DescriptionNateglinide is a N-acylated D-phenylalanine marketed in Japan as novel orally active insulinotropic agent for the treatment of type-2 diabetes mellitus. It belongs to the class of nonsulfonylureas and shows some structural similarity to repaglinide, the only other representative in this family. In single pancreatic beta-cells isolated from rats, Nateglinide was found to specifically block the ATP-sensitive K+ channel resulting in an increase in intracellular calcium concentration. This primary action would underlie the mechanism by which Nateglinide markedly stimulates or potentiates, depending on glucose concentrations, insulin secretion from pancreatic beta-cells. Clinical studies demonstrated a good safety profile with a low potential for hypoglycemia. The pharmacokinetic profile was consistent with the changes of the blood glucose and plasma insulin level. Interestingly, Nateglinide exerts a rapid onset and short duration of action due to a rapid absorption and clearance. Unlike other similar agents, Nateglinide suppresses postprandial glucose elevations.
Chemical PropertiesCyrstalline Solid
OriginatorAjinomoto (Japan)
UsesAn Amino-acid derivative that stimulates insulin secretion. Used as an antidiabetic
Usesantidiabetic KATP channel blocker
DefinitionChEBI: An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-ad inistered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.
Brand nameStarlix (Novartis);Fastic;Starsis.
General DescriptionAlthough nateglinide, N-(4-isopropylcyclohexanecarbonyl)-D-phenylalanine (Starlix), belongs tothe metaglinides, it is a phenylalanine derivative and representsa novel drug in the management of type 2 diabetes.
General DescriptionNateglinide (Starlix) is D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-; or (-)-N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine. Itis noteworthy that, although nateglinide is much less potenton a dosage basis than is repaglinide and most of the sulfonylureas,this drug seems to exhibit unique molecularpharmacodynamics. Nateglinide closes ATP-sensitive K channels some threefold more rapidly than repaglinide, andexhibits an off-rate twice as fast as that of glyburide orglimepiride and five times faster than repaglinide. Thesecharacteristics are reflected by the systemic pharmacodynamicsof this drug, translating clinically to improvedsafety, among other apparent benefits.
Mechanism of actionApproved in the United States in late 2000, nateglinide is a rapidly absorbed insulin secretagogue that has a mechanism of action similar to that of repaglinide, with effects appearing within 20 minutes following oral dosing. Bioavailability is 73%, and it is 98% protein bound, primarily to albumin. Nateglinide is tissue selective, with low affinity for cardiac and skeletal muscle.
MetabolismIt is metabolized in the liver, with 16% excreted in the urine unchanged. The major metabolites are hydroxyl derivatives (CYP2C9, 70%; CYP3A4, 30%) that are further conjugated to the glucuronide derivatives.
Nateglinide Preparation Products And Raw materials
Tag:Nateglinide(105816-04-4) Related Product Information
Repaglinide Glimepiride Mitiglinide calcium Glycine, N-[(4-ethylcyclohexyl)carbonyl]- (9CI) HYDROCINNAMIC-D5 ACID N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenyl Alanine DL-PHENYL-D5-ALANINE N-ACETYL-D-PHENYLALANINE D-PHENYL-D5-ALANINE Nateglinide Phenprobamate Propane Bis(cyclohexanone)oxaldihydrazone PHENYL RESIN Phenyl salicylate Phenylacetic acid Diphenyl ether PHENYL VALERATE